Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab for GVHD Prophylaxis in Haploidentical/Partially Matched Stem Cell Transplant
NCT01116232Phase 2Terminated
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Aug 2010
- Primary completion
- May 2013
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sirolimus, tacrolimus + Wuzhi capsule, antithymocyte globulin rabbit, rituximab in graft-versus-host disease (GVHD), sponsored by Barbara Ann Karmanos Cancer Institute. Started Aug 2010; status: terminated.
02
Drugs
sirolimustacrolimus + Wuzhi capsuleantithymocyte globulin rabbitrituximab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01116232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01116232.